ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Insmed Incorporated (INSM) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Insmed Incorporated (INSM)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: ANAC, CBPO, LJPC, RGEN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

Insmed Incorporated© quotemedia

Company Profile

Insmed Incorporated, a development-stage biopharmaceutical company, develops inhaled treatments for serious lung infections. Its primary product candidate, ARIKACE is a differentiated inhaled antibiotic supported by positive Phase II results for treating serious lung infections due to susceptible bacteria. The company’s IPLEX is a proprietary protein product that is being evaluated in the treatment of retinopathy of prematurity. It out licensed the rights of three early stage development products, including Inhaled CISPLATIN Lipid Complex, rhIGFBP-3, and INSM-18. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.

Recent News: Insmed Incorporated